Hims & Hers Health Inc (NYSE:HIMS)’s traded shares stood at 17.64 million during the last session, with the company’s beta value hitting 1.63. At the close of trading, the stock’s price was $33.88, to imply an increase of 7.59% or $2.39 in intraday trading. The HIMS share’s 52-week high remains $72.98, putting it -115.41% down since that peak but still an impressive 66.94% since price per share fell to its 52-week low of $11.20. The company has a valuation of $7.53B, with an average of 21.72 million shares in intraday trading volume over the past 10 days and average of 21.11 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Hims & Hers Health Inc (HIMS), translating to a mean rating of 2.47. Of 13 analyst(s) looking at the stock, 0 analyst(s) give HIMS a Sell rating. 1 of those analysts rate the stock as Overweight while 5 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.21.
Hims & Hers Health Inc (NYSE:HIMS) trade information
After registering a 7.59% upside in the last session, Hims & Hers Health Inc (HIMS) has traded red over the past five days. The 5-day price performance for the stock is -0.15%, and -42.09% over 30 days. With these gigs, the year-to-date price performance is 40.12%. Short interest in Hims & Hers Health Inc (NYSE:HIMS) saw shorts transact 51.84 million shares and set a 1.68 days time to cover.
The extremes give us $21 and $68 for target low and target high price respectively. As such, HIMS has been trading -100.71% off suggested target high and 38.02% from its likely low.
Hims & Hers Health Inc (HIMS) estimates and forecasts
The rating firms project that company’s revenue will grow 57.93% compared to the previous financial year.
Revenue forecast for the current quarter as set by 11 analysts is 535.21M. Meanwhile, for the current quarter, a total of 11 analyst(s) estimate revenue growth to 564.91M.Earnings reports from the last fiscal year show that sales brought in 278.17M and 315.65M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 92.40% before jumping 78.97% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 17.22% for the past 5-year period. While 2025 is set for a 12.77% return in earnings, projections for the next 5 years are at 31.05% annually.
HIMS Dividends
Hims & Hers Health Inc has its next earnings report out on 2025-Feb-23. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Hims & Hers Health Inc (NYSE:HIMS)’s Major holders
Hims & Hers Health Inc insiders hold 11.25% of total outstanding shares, with institutional holders owning 79.06% of the shares at 89.07% float percentage. In total, 79.06% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 16.47 million shares (or 7.7166% of shares), all amounting to roughly $332.55 million.
The next major institution holding the largest number of shares is BLACKROCK INC. with 14.57 million shares, or about 6.8278% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $294.25 million.
We also have iShares Core S&P Small-Cap ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Hims & Hers Health Inc (HIMS) shares. Going by data provided on Jan 31, 2025, iShares Core S&P Small-Cap ETF holds roughly 12.29 shares. This is just over 5.75% of the total shares, with a market valuation of $416.22 million. Data from the same date shows that the other fund manager holds a little less at 5.27, or 2.47% of the shares, all valued at about 178.61 million.
